On November 21, Iovance Biotherapeutics, Inc. fell 5.06% in Regular Trading, trading at $6.935 per share, with turnover of $45.10 million.
The latest company update was a conference participation announcement disclosed on November 13, which did not include new clinical, regulatory, or financial developments, leaving the shares without a fresh catalyst.
Earlier, the company reported third-quarter EPS of fall $0.05, better than consensus expectations for a wider loss, while revenue rose to $121.5 million from $67.5 million a year earlier and topped market forecasts. Management also reaffirmed full-year product revenue guidance of $410 million to $420 million. Despite those stronger reported figures, the recent news flow has been limited mainly to event appearances rather than new operating milestones.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments